Leber Congenital Amaurosis 10
📧 Sign up to get email alerts when something new happens for Leber Congenital Amaurosis 10.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: Single Ascending Dose Study in Participants With LCA10 [Phase 1, Phase 2]
Clinical trial update for a single ascending dose study in Leber Congenital Amaurosis 10, a Phase 1/2 trial involving Editas Medicine; curre…
-
CLINICAL_TRIALS trial_result · 2022-03-25Clinical Trial Update: An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. [Phase 2, Phase 3]
An open-label dose-escalation study with a double-masked, randomized design is evaluating the safety and tolerability of Sepofarsen in child…
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) [Phase 2, Phase 3]
A clinical trial evaluating efficacy, safety, tolerability, and exposure of repeat-dose Sepofarsen (QR-110) in Leber Congenital Amaurosis 10…